Tag Archives: Cotellic

May, 2018

November, 2015

  • 23 November

    Roche’s Melanoma Drug Performs Well in Early-Stage Study

    Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the pivotal coBRIM study, which showed that Cotellic (cobimetinib) in combination with Zelboraf (vemurafenib) helped people with BRAF V600E and V600K mutation-positive unresectable or metastatic melanoma live significantly longer (overall survival; OS) than with Zelboraf alone.1 Cotellic plus Zelboraf reduced …

  • 10 November

    FDA Approves Cotellic as part of a Combination Treatment for Skin Cancer

    Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Cotellic™ (cobimetinib) for the treatment of people with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf ®(vemurafenib). Cotellic and Zelboraf are not …